Incyte stock falls 1.57 percent as Wells Fargo raises target

Published on 10/04/2026 at 13:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Incyte stock fell 1.57 percent to USD 115.30 on October 2, 2026, while Wells Fargo lifted its target to USD 128. Q2 revenue rose 37.7 percent.

Isometrische 3D-Illustration der Pharmawertschöpfungskette vom Labor bis zum Krankenhaus — Isometrische 3D-Wertschöpfungskette der Biopharmazie von Labor bis Patient, Incyte Prozess ISIN US45337C1027, Illustration mit AI erstellt.

Incyte stock (ISIN US45337C1027) fell 1.57 percent to USD 115.30 on Nasdaq on October 2, 2026, as the latest session left the shares 13.0 percent below their 52-week high of USD 132.60. The more immediate analyst signal came on October 1, 2026, when MarketBeat reported that Wells Fargo raised its price target from USD 116 to USD 128 while retaining an Equal-Weight rating.

Wells Fargo lifts target to USD 128

The target increase is notable because it came alongside a neutral rating rather than a bullish upgrade. At USD 128, the Wells Fargo target stands 11.0 percent above the October 2 reference price of USD 115.30, giving the analyst action a measured rather than aggressive profile.

MarketBeat reported a Moderate Buy consensus based on 25 analyst ratings, with an average price target of USD 126.15 and an individual high of USD 155.00. The average target is 9.4 percent above the October 2 price, although the stock remains 13.0 percent below its 52-week high.

Q2 growth raises the earnings bar

Incyte's second-quarter 2026 results provide the operating backdrop for the target revisions. According to MarketBeat on October 1, 2026, quarterly EPS reached USD 3.09 versus consensus of USD 2.15, while revenue rose 37.7 percent year over year to USD 1.67 billion.

Zacks reported that Incyte raised its 2026 net product revenue guidance to USD 5.13-5.26 billion from USD 4.77-4.94 billion. The same report said Opzelura guidance increased to USD 1.05-1.10 billion from USD 750-790 million, making product mix a central test for the growth case.

Incyte stock stays below USD 120

At USD 115.30, Incyte stock was trading 13.0 percent below its 52-week high and 39.2 percent above its 52-week low of USD 82.82 on October 2, 2026. The combination of a 1.57 percent daily decline, higher guidance and a USD 126.15 consensus target leaves execution on the pipeline as the key valuation question.